Parameters | 90Y-DOTATOC* | 177Lu-DOTATATE | P value |
---|---|---|---|
No. of patients | 28 | 37 | |
Men/Women | 13/15 | 17/20 | — |
Age (y) (range) | 56 ± 9 (40–75) | 58 ± 12 (20–79) | — |
Diabetes (%) | 4 (14%) | 7 (19%) | — |
Hypertension (%) | 7 (25%) | 7 (19%) | — |
Baseline CLR (mL/min/1.73 m2) (range) | 92.5 ± 25.7 (45.3–167.6) | 93.9 ± 22.3 (45.2–154.4) | NS |
Cumulative renal dose (Gy) (range) | 26.9 ± 3.0 (18.3–38.7) | 19.8 ± 4.3 (7.3–26.7) | <0.001 |
Highest renal dose per cycle (Gy) (range) | 12.6 ± 7.1 (5.9–26.9) | 4.8 ± 1.5 (1.8–7.8) | <0.001 |
Follow-up (y) (range) | 3.2 ± 1.4 (1.5–5.5) | 2.6 ± 0.7 (1.7–4.0) | 0.04 |
Median measurements per patient (range) | 16 (5–53) | 10 (6–27) | <0.001† |
Median change in CLR (%/y) (range) | −7.3 (−56–10.9) | −3.8 (−40.2–6) | 0.06†§ |
Width of 95% Cl†† (%/y) (range) | 9.7 ± 7.1 (3–31) | 12.2 ± 6.5 (2–26) | NS |
↵* Mean values ± SD. Independent samples T-tests for continuous variables with sufficiently normal distributions and χ2 tests for ordinate variables.
↵† Mann-Whitney test.
↵†† Width of 95% CI denotes average width of 95% CIs of calculated percentage changes in CLR for individual patients.
↵§ Range of values was wider in the 90Y-DOTATOC group (Moses extreme reactions test, P < 0.01).
NS = not significant.